Pulling the wool over a pathogen’s eyes: Llama nanobody inhibitors of the bacterial SOS response

Cirz, 2005, Inhibition of mutation and combating the evolution of antibiotic resistance, PLoS Biol., 3, e176, 10.1371/journal.pbio.0030176 De Genst, 2006, Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies, Proc. Natl. Acad. Sci. USA, 103, 4586, 10.1073/pnas.0505379103 Kelley, 2006, Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon, Mol. Microbiol., 62, 1228, 10.1111/j.1365-2958.2006.05444.x Luo, 2001, Crystal structure of LexA: a conformational switch for regulation of self-cleavage, Cell, 106, 585, 10.1016/S0092-8674(01)00479-2 Maso, 2022, Nanobodies targeting LexA autocleavage disclose a novel suppression strategy of SOS-response pathway, Structure, 30, 1479, 10.1016/j.str.2022.09.004 Mei, 2022, Research progress and applications of nanobody in human infectious diseases, Front. Pharmacol., 13, 963978, 10.3389/fphar.2022.963978 Mo, 2018, Inhibitors of LexA Autoproteolysis and the bacterial SOS response discovered by an Academic-Industry Partnership, ACS Infect. Dis., 4, 349, 10.1021/acsinfecdis.7b00122 Muyldermans, 2013, Nanobodies: Natural single-domain antibodies, Annu. Rev. Biochem., 82, 775, 10.1146/annurev-biochem-063011-092449 Simmons, 2008, The SOS regulatory Network, EcoSal Plus, 3, 10, 10.1128/ecosalplus.5.4.3 Wigle, 2009, Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli., J. Biomolecular Screening, 14, 1092, 10.1177/1087057109342126